

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Tong Ren Tang Technologies Co. Ltd.
北京同仁堂科技發展股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1666)

VOLUNTARY ANNOUNCEMENT
ENTERING INTO THE CAPITAL INCREASE AGREEMENT

This announcement is made by Tong Ren Tang Technologies Co. Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the shareholders (the “**Shareholders**”) and potential investors of the Company informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 16 February 2023, the Company, Beijing Tong Ren Tang Chinese Medicine Company Limited (“**Tong Ren Tang Chinese Medicine**”), a subsidiary of the Company, whose shares are listed on the Hong Kong Stock Exchange (stock code: 3613), Beijing Tong Ren Tang WM Dianorm Biotech Co., Ltd. (“**Tong Ren Tang WM Dianorm**”), a subsidiary of the Company, and Jianzhijia Health-Chain Co., Ltd. (健之佳醫藥連鎖集團股份有限公司) (“**Jianzhijia**”, whose shares are listed on the Shanghai Stock Exchange, stock code: 605266.SH) entered into a capital increase agreement (the “**Capital Increase Agreement**”). Pursuant to the Capital Increase Agreement, Jianzhijia has agreed to make capital contribution in the amount of RMB33,345,000 to Tong Ren Tang WM Dianorm. Upon completion, the registered capital of Tong Ren Tang WM Dianorm will be increased from USD3,000,000 to USD 4,000,000, and Tong Ren Tang WM Dianorm will be interested as to 45%, 30% and 25% by the Company, Tong Ren Tang Chinese Medicine and Jianzhijia, respectively. Tong Ren Tang WM Dianorm will remain as a subsidiary of the Company upon the completion of the abovementioned capital increase.

Upon completion of the capital increase, Tong Ren Tang WM Dianorm will take full advantage of professional management concept and sales channel resources of Jianzhijia, improve development and cooperation, and enhance the competitive advantage of products of Tong Ren Tang WM Dianorm. The Directors (including independent non-executive directors) are of the view that the terms and conditions of the Capital Increase Agreement are fair and reasonable, the transaction contemplated thereunder was entered into on normal or better commercial terms in the ordinary and usual course of business of the Company, and are in the interests of the Company and the Shareholders as a whole.

As at the date of this announcement, to the knowledge and belief of the Directors after having made all reasonable enquiries, Jianzhijia is a third party independent of the Company and its connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”). Therefore, the transaction contemplated under the Capital Increase Agreement does not constitute a connected transaction of the Company under Chapter 14A of the Hong Kong Listing Rules. In addition, as all applicable percentage ratios in respect of the transaction contemplated under the Capital Increase Agreement under Rule 14.07 of the Hong Kong Listing Rules are less than 5%, the transaction contemplated under the Capital Increase Agreement does not constitute a notifiable transaction under Chapter 14 of the Hong Kong Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Tong Ren Tang Technologies Co. Ltd.
Gu Hai Ou
Chairman of the Board

Beijing, the PRC
16 February 2023

As at the date of this announcement, the Board comprises Mr. Gu Hai Ou, Mr. Wang Yu Wei and Ms. Feng Zhi Mei as executive Directors, Mr. Jin Tao, Ms. Wang Chun Rui and Ms. Feng Li as non-executive Directors, Mr. Ting Leung Huel, Stephen, Ms. Chan Ching Har, Eliza and Mr. Zhan Yuan Jing as independent non-executive Directors.